Q-omics provides the consensus-scored ZNF80 profile across patient tissues and cancer cell-line models. ZNF80 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZNF80 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ZNF80 RNA expression shows 14,987 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where ZNF80 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF80 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF80 survival associations across molecular data types. ZNF80 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF80 RNA expression–survival associations across cancer types. High ZNF80 expression shows unfavorable associations in KIRC, but favorable associations in SKCM, HNSC, LUAD, BRCA and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZNF80 RNA expression.
This table summarizes ZNF80 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF80. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF80 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, HNSC, STAD and BRCA. The KIRC box plot shows higher ZNF80 RNA expression in tumor versus normal tissue (log2 FC = +0.200, t-test p < 0.001).
This table shows molecular features associated with ZNF80 in patient tissues and cancer cell lines. In patient samples, ZNF80 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF80 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
